

CytomX Therapeutics, Inc.  
Form 4  
March 27, 2017

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
THIRD ROCK VENTURES LP

(Last) (First) (Middle)

29 NEWBURY STREET, 3RD FLOOR

(Street)

BOSTON, MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol  
CytomX Therapeutics, Inc. [CTMX]

3. Date of Earliest Transaction (Month/Day/Year)  
03/23/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

\_\_\_ Director \_\_\_X\_\_\_ 10% Owner  
\_\_\_ Officer (give title below) \_\_\_ Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|
|                                 |                                      |  | Code                           | V   | Amount  | (A) or (D)   | Price   |
| Common Stock                    | 03/23/2017                           |  | S                              |   | 1,000,000   | D  | \$ 17.0002  |
| Common Stock                    | 03/27/2017                           |  | S                              |   | 650,000   | D  | \$ 18.0003  |
| Common Stock                    |                                      |  |                                |   |   |  | (2)   |
| Common Stock                    |                                      |  |                                |   |   |  | 59,776  |
| Common Stock                    |                                      |  |                                |   |   |  | 59,776  |
| Common Stock                    |                                      |  |                                |   |   |  | 59,777  |
|                                 |                                      |  |                                |   |   |  | D (1)   |
|                                 |                                      |  |                                |   |   |  | D (1)   |
|                                 |                                      |  |                                |   |   |  | D (3)   |
|                                 |                                      |  |                                |   |   |  | D (4)   |
|                                 |                                      |  |                                |   |   |  | D (5)   |

Edgar Filing: CytomX Therapeutics, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|--|

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| THIRD ROCK VENTURES LP<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116       |               | X         |         |       |
| Third Rock Ventures GP, L.P.<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116 |               | X         |         |       |
| TRV GP, LLC<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116                  |               | X         |         |       |
| LEVIN MARK J<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116                 |               | X         |         |       |
| STARR KEVIN P<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116                |               | X         |         |       |
| TEPPER ROBERT I<br>29 NEWBURY STREET, 3RD FLOOR<br>BOSTON, MA 02116              |               | X         |         |       |

## Signatures

|   |            |
|---|------------|
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P., general partner of Third Rock Ventures, L.P. | 03/27/2017 |
| __Signature of Reporting Person   | Date       |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC, general partner of Third Rock Ventures GP, L.P.   | 03/27/2017 |
| __Signature of Reporting Person   | Date       |
| /s/ Kevin Gillis, Chief Financial Officer of TRV GP, LLC  | 03/27/2017 |
| __Signature of Reporting Person   | Date       |
| /s/ Kevin Gillis by power of attorney for Mark Levin  | 03/27/2017 |
| __Signature of Reporting Person   | Date       |
| /s/ Kevin Gillis by power of attorney for Kevin Starr   | 03/27/2017 |
| __Signature of Reporting Person   | Date       |
| /s/ Kevin Gillis by power of attorney for Robert I. Tepper  | 03/27/2017 |
| __Signature of Reporting Person   | Date       |

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

These shares are directly held by Third Rock Ventures, L.P. ("TRV"). The general partner of TRV is Third Rock Ventures GP, L.P.

("TRV GP"). The general partner of TRV GP is TRV GP, LLC ("TRV GP LLC"). The individual managers of TRV GP LLC are Mark

- (1) Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP, TRV GP LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.

This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.45, inclusive.

- (2) Each of the reporting persons undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
- (3) These shares are directly held by Starr.
- (4) These shares are directly held by Levin.
- (5) These shares are directly held by Tepper.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.